Table 2 Clinical and pathological data of the GIL group and the non-GIL group [n (%), \(\overline{x }\) ± s, M (Q1, Q3)].
Item | GIL Group (n = 76) | Non-GIL Group (n = 125) | t/χ2/Z value | P-value |
|---|---|---|---|---|
Sex | ||||
M | 53 (69.7) | 73 (58.4) | 2.597 | 0.107 |
F | 23 (30.3) | 52 (41.6) | ||
Age | 51.80 ± 10.19 | 47.74 ± 11.39 | 2.548 | 0.012 |
Hypertension | ||||
Yes | 41 (53.9) | 51 (40.8) | 3.291 | 0.07 |
No | 35 (46.1) | 74 (59.2) | ||
Serum uric acid level (μmol/L) | 403.69 ± 79.64 | 338.02 ± 70.84 | 6.007 | < 0.001 |
Serum creatinine (μmol/L) | 67.04 ± 13.03 | 64.36 ± 13.13 | 1.408 | 0.161 |
eGFR [mL/(min.1.73m2)] | 104.97 ± 8.83 | 108.83 ± 10.76 | − 2.636 | 0.009 |
Hemoglobin (g/L) | 135.02 ± 15.28 | 136.29 ± 16.21 | − 0.550 | 0.583 |
WBC (× 109/L) | 6.37 (5.325, 7.975) | 6.34 (5.04, 7.29) | − 0.746 | 0.46 |
PLT (× 109/L) | 242 (211, 290) | 251 (209, 300) | − 0.018 | 0.986 |
Serum albumin (g/L) | 25.67 ± 5.39 | 23.75 ± 5.60 | 2.362 | 0.019 |
Proteinuria (g/24 h) | 5.246 (3.094, 7.534) | 5.384 (3.501, 8.147) | -0.633 | 0.527 |
Blood urine (/μL) | 27.92 (16.85, 65.225) | 35.6 (19.2, 74.4) | − 1.2 | 0.23 |
TC (mmol/L) | 7.24 (6.045, 8.475) | 7.17 (5.62, 9.23) | − 0.345 | 0.73 |
TG (mmol/L) | 2.03 (1.485, 2.77) | 1.95 (1.44, 2.62) | − 0.784 | 0.433 |
LDL (mmol/L) | 4.97 (3.915, 6.095) | 4.63 (3.45, 5.98) | − 0.577 | 0.564 |
anti-PLA2R(RU/ml) | 38.09(17.95,74.14) | 31.47(5.33,97.48) | − 1.043 | 0.297 |
Glomerular sclerosis | ||||
No | 51 (67.1) | 93 (74.4) | 1.238 | 0.266 |
Yes | 25 (32.9) | 32 (25.6) | ||
Glomerular segmental sclerosis | ||||
No | 69 (90.8) | 107 (85.6) | 1.169 | 0.28 |
Yes | 7 (9.2) | 18 (14.4) | ||
Renal tubular atrophy/interstitial fibrosis | ||||
No | 8 (10.5) | 50 (40.0) | 20.0 | < 0.001 |
Yes | 68 (89.5) | 75 (60.0) | ||
Arteriolar hyalinosis | ||||
No | 42(55.3%) | 84(67.2%) | 2.897 | 0.09 |
Yes | 34(44.7%) | 41(32.8%) | ||
Arteriolosclerosis | ||||
No | 53(69.7%) | 105(84.0%) | 5.718 | 0.017 |
Yes | 23(30.3%) | 20(16.0%) | ||
